Absci vs Insilico Medicine

Side-by-side comparison of AI visibility scores, market position, and capabilities

Insilico Medicine leads in AI visibility (43 vs 30)
Absci logo

Absci

GrowthBiotechnology

AI Drug Creation

Absci is an AI drug creation company that combines generative AI with a synthetic biology platform to design novel therapeutic proteins from the ground up.

AI VisibilityBeta
Overall Score
D30
Category Rank
#1 of 1
AI Consensus
75%
Trend
up
Per Platform
ChatGPT
26
Perplexity
37
Gemini
29

About

Absci is a publicly traded AI drug creation company founded in 2011 that went public in 2021 and has repositioned around generative AI for drug design. The company operates an integrated platform that uses generative AI to design novel antibodies and proteins, then validates them using high-throughput expression and biological assay systems in its own wet lab infrastructure. Absci's approach treats drug discovery as a generative design problem, using AI to propose protein sequences with desired therapeutic properties and then rapidly testing millions of candidates to identify viable drug leads. The company has established drug creation partnerships with major pharmaceutical companies including AstraZeneca, Merck, and EQT Life Sciences. Absci's technical differentiation lies in its ability to close the loop between AI-generated protein designs and experimental validation at unprecedented scale. The company represents a new category of AI-native biopharmaceutical company that combines computational and wet-lab capabilities to create drugs not discoverable through traditional means.

Full profile
Insilico Medicine logo

Insilico Medicine

ChallengerLife Sciences & BioTech

Drug Discovery & Development

Insilico Medicine (HKEX: 3696) raised $293M, posted $56.2M revenue in 2025, and inked a $2.75B Eli Lilly deal in 2026 using generative AI to discover drug targets in cancer and CNS.

AI VisibilityBeta
Overall Score
C43
Category Rank
#1 of 1
AI Consensus
66%
Trend
up
Per Platform
ChatGPT
39
Perplexity
46
Gemini
38

About

Insilico Medicine is a clinical-stage biotechnology company founded in 2014 that leverages generative AI for drug discovery and development. Headquartered in Boston with offices in Hong Kong and New York, the company has built AI platforms utilizing deep generative models, reinforcement learning, and transformers to discover novel drug targets and generate molecular structures with desired properties. Its pipeline spans cancer, fibrosis, CNS diseases, infectious diseases, autoimmune conditions, and aging-related diseases.

Full profile

AI Visibility Head-to-Head

30
Overall Score
43
#1
Category Rank
#1
75
AI Consensus
66
up
Trend
up
26
ChatGPT
39
37
Perplexity
46
29
Gemini
38
31
Claude
48
30
Grok
35

Key Details

Category
AI Drug Creation
Drug Discovery & Development
Tier
Growth
Challenger
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Absci
AI Drug Creation
Only Insilico Medicine
Drug Discovery & Development
Insilico Medicine is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.